New Covid-19 antigen test: Fast and reliable results in just 15 minutes
more
Stories about Medizin
- Language:
- Media:
- Period:
- Period:Total
Regulatory breakthrough for BrainRepair UG start-up - Stem cell treatment for newborns /EMA Orphan Drug Designation is followed by agreement on Paediatric Investigation Plan
moreNTT DATA Business Solutions AG
2it.lifesciences for plasma: Accelerator for the human blood plasma manufacturing industry
moreHARTMANN launches Mission: Infection Prevention - how prevention is contagious
moreUMIT - The Health & Life Sciences University
University UMIT TIROL publishes the first population model to evaluate benefits and harms of universal salt iodization
Hall in Tirol (ots) - An article recently published by Schaffner and colleagues in the medical journal "Thyroid" summarizes the results of a decision-analytic population modeling study evaluating the benefits and harms of universal salt iodization. Iodine is a micronutrient that is essential for the production of ...
moreSysmex Inostics' Liquid Biopsy Testing Benefits Metastatic Pancreatic Cancer Patient Management
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating cell-free tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study investigating the utility of cfDNA-based markers using the highly sensitive OncoBEAM RAS assay, an enhanced ...
more
Sysmex Inostics' OncoBEAMTM RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating RAS mutation status in circulating tumor DNA (ctDNA) of colorectal cancer (CRC) patients undergoing anti-EGFR ...
moreEffectiveness and efficiency of targeted intra-operative single dose radiotherapy for breast cancer patients confirmed
Jena, Germany (ots) - New long-term results from the international TARGIT-A breast cancer study, based on ZEISS technology, have been published [1] Use of targeted intra-operative radiotherapy (TARGIT), as a single dose - with ZEISS INTRABEAM - directly after removal of a tumor, confirmed as non-inferior, when ...
moreSysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing
Baltimore, Maryland (ots) - Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating the performance of plasma RAS mutation testing with OncoBEAM RAS CRC as compared to standard of care ...
moreDr. Rath Education Services BV
Micronutrient Combination Suppresses Cell 'Entry Door' For Coronavirus
moreIgNova files patent application on antibody against COVID-19
Visbek, Germany (ots) - IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (IgY). The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the ...
moreHauck Aufhäuser Lampe Privatbank AG
ÓSKARE CAPITAL SAS launches ÓSKARE Fund I focusing on innovative European companies in the medical cannabinoid industry
Paris, FRANCE & Dublin, IRELAND (ots) - ÓSKARE CAPITAL SAS today launches ÓSKARE Fund I together with cannabinoid industry veteran Bruce Linton. The EU based fund targets next generation cannabinoid therapies and related industry infrastructure, leveraging the expertise and track record of the founding team in ...
more
HAPA pharm receives GMP certification / Quality assured medical cannabis products
Dortmund (ots) - HAPA pharm ("HAPA" or the "Company") operates production facilities in North Macedonia to grow and process medical cannabis for the sale of pharmaceutical cannabis flos and extracts. On May 1st 2020, the Company has successfully received GMP (Good Manufacturing Practice) approval for both facilities. This milestone demonstrates HAPA's commitment ...
more- 2
Innovation: Intelligent bacteria demonstrate high efficacy in the treatment of widespread disease irritable bowel syndrome with typical symptoms of recurrent diarrhoea, abdominal pain, bloating and constipation
more - 2
FLUXERGY ANNOUNCES $30 MILLION TO EXPAND MANUFACTURING CAPACITY OF ITS ONE-HOUR POINT-OF-CARE DIAGNOSTIC TESTING SYSTEM IN RESPONSE TO COVID-19
more ATMOS MedizinTechnik GmbH & Co. KG
2Face protection against droplet infection from ATMOS
more- 2
Fielmann starts producing protective glasses
more Elastrin Therapeutics develops new approach against "Inflammatory Storm" that kills most Corona patients
Greenville South Carolina (ots) - A previously untested approach to preventing the most severe outcomes of lung diseases, including COVID-19, has been developed by Elastrin Therapeutics based on targeting damaged elastic fiber that leads to impaired lung function. The company has developed the world's first ...
more
Using Health Data: A Sustainable Alternative to Big Tech / Ocean Protocol and Zühlke team up to push an open data economy for healthcare (FOTO)
moreSysmex Inostics' updated SafeSEQ Breast Cancer Panel advances novel clinical uses of ctDNA through quantitative testing
Baltimore, Maryland (ots) - Building on the ultra-high sensitivity SafeSEQ Breast Cancer Panel circulating tumor DNA (ctDNA) test launched at the American Association of Cancer Research 2019 annual meeting, Sysmex Inostics has updated the test to provide additional key information for investigation of the validity ...
moreEuropean Society for Medical Oncology (ESMO)
2ESMO supports women in South Africa to become autonomous workers
moreSysmex Inostics and Oxford Gene Technology plasma and tissue sequencing show clearance of ctDNA correlates with pathologic complete response in breast cancer patients during neoadjuvant treatment
Hamburg, Germany and Baltimore, Maryland (ots) - Pathologist Dr. Vincente Peg of the Vall d´Hebron University Hospital (Barcelona Spain) and colleagues have presented a correlation between the clearance of circulating tumor DNA (ctDNA) in HER2-positive or triple-negative breast cancer patients undergoing ...
moreSysmex Inostics announces first results of tissue-independent liquid biopsy for early stage breast cancer mutation characterization and monitoring using ultra-sensitive SafeSEQ technology
Hamburg, Germany and Baltimore, Maryland (ots) - New data presented by Dr. Ben Ho Park, Professor of Medicine and Director of Precision Oncology at Vanderbilt University and colleagues at the recent San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas demonstrated a potential utility for monitoring ...
moreHitachi Medical Systems Europe Holding AG
2Hitachi and Centre Léon Bérard cancer center in Lyon to launch a research collaboration in the fight against cancer with AI
more
Global Health Centre, The Graduate Institute of International and Development Studies
The Lancet and Financial Times partner for first joint Commission on Governing health futures 2030: Growing up in a digital world
One documentmoreSysmex Inostics publishes first feasibility study of NGS-based liquid biopsy to complement early breast cancer screening by imaging
Hamburg/Baltimore (ots) - Using Sysmex Inostics' novel SafeSEQ next-generation sequencing cell-free DNA technology, investigators from the Biomedical Research Institute of Malaga [(IBIMA)-CIMES-UMA, Malaga Spain] and collaborators have published the first pilot study to examine the use of a non-invasive liquid ...
moreVBS VetVerlag, Buchhandel und Seminar GmbH
World's Elite Specialists in Veterinary Rehabilitation- and Sports Medicine Meet in Ghent - Eagerly Awaited Standard Work is Going to be Presented by the Main Authors
moreSysmex obtains Japanese manufacturing and marketing approval for the first blood-based RAS mutation testing for colorectal cancer
Kobe, Japan (ots) - Sysmex Corporation has obtained Japanese manufacturing and marketing approval for the OncoBEAM(TM) RAS CRC Kit, used for blood-based circulating tumor DNA (ctDNA) molecular testing of mutations in the RAS gene for advanced colorectal cancer patients. With clinically-validated high sensitivity and ...
moreLiquid Biopsy performance comparison of Sysmex Inostics OncoBEAM RAS CRC and BioCartis Idylla ctKRAS testing published in Scientific Reports (Nature Journal)
Hamburg, Germany (ots) - Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces publication of a study comparing the performance of plasma RAS mutation detection by two commercial liquid biopsy testing platforms, the OncoBEAM(TM) ...
moreSysmex Inostics OncoBEAM(TM)-EGFR digital PCR liquid biopsy demonstrates two-fold higher detection of p.T790M mutations in 183 NSCLC patients in comparison study
Hamburg/Baltimore (ots) - Sysmex Inostics announces the publication of clinical research conducted as part of the CIRculating CANcer (CIRCAN) Program at the Lyon Cancer Institute (Lyon, France) comparing the performance of Sysmex Inostics BEAMing (beads, emulsion, amplification, and magnetics) assay for EGFR ...
more
Previous12345678Next